Maui General Store and Trinity BioGenics Sign Definitive Merger Agreement - 500 Beiträge pro Seite

[wayne99]

Gestern nachbörsliche Meldung:

USA: MAUG.OB - in D A0F60Y

Press Release Source: Maui General Store

Maui General Store and Trinity BioGenics Sign Definitive Merger Agreement
Tuesday December 13, 1:00 am ET

HANA, Hawaii, Dec. 13, 2005 (PRIMEZONE) -- Maui General Store, Inc. (OTC BB:MAUG.OB - News) and Palmera Holdings, Inc., dba Trinity BioGenics, announced today that a definitive agreement has been reached to merge the two companies. Trinity BioGenics is a biotechnology company engaged in research and development of unique adult stem cell procedures and patient-specific immune therapies with applications for various conditions and diseases, with a current clinical focus on therapies for heart disease.

ADVERTISEMENT
Stem cell research is a high-profile subsection of the biotech industry and is receiving a tremendous amount of attention from society in general as well as the investment community. Members of the scientific community, and increasingly members of the investment community, recognize the great potential that lies in the research and development of therapies and procedures using various types of adult stem cells. ``We are excited to have reached an agreement with Trinity BioGenics,`` stated Maui General Store CEO Richard Miller, adding that ``we are looking forward to a long and prosperous relationship with a truly visionary company.``

For more information on Trinity BioGenics go to their website:http://www.TrinityBioGenics.com

The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company`s operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company`s dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.

The Maui General Store logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1128


Contact:

Maui General Store, Inc.
Richard Miller, President and CEO
[phone]
http://www.MauiGeneralStore.com

Source: Maui General Store

[wayne99]

Der Merger wurde am 18.10.05 als LOI gemeldet und gestern nachb. der Vollzug gemeldet:

Press Release Source: Maui General Store

Maui General Store Signs Letter of Intent to Merge with Stem Cell Research and Technology Company
Tuesday October 18, 7:00 am ET

HANA, Hawaii, Oct. 18, 2005 (PRIMEZONE) -- Maui General Store, Inc. (OTC BB:MAUG.OB - News) announced today that it has signed a letter of intent to merge with Palmera Holdings, Inc., dba Trinity BioGenics, an emerging adult stem cell technology company. Florida-based Trinity BioGenics has distinguished itself within a growing sector of research firms that focus on the use of adult stem cell tissues to develop revolutionary medical procedures. Trinity`s technological accomplishments have and will continue to contribute to a redefinition of patient treatments and therapies for chronic ailments such as heart disease, diabetes, cancer, Alzheimer`s disease and Parkinson`s disease.

ADVERTISEMENT
Possessing worldwide licensing rights for the commercialization of specific uses of adult stem cells for cell therapy, Trinity also holds similar rights to the development of autologous vaccines for targeting the immune system, biological response modifiers for immune modulations, as well as novel plant extracts for biological medicines. These research frontiers are among the most sought-out by the United States Food & Drug Administration, and Trinity`s current licenses have been described as five years ahead of comparable research currently under development in the United States. Recently gaining increased attention from investors due to data disclosed by researchers on September 20, that human adult stem cells helped regenerate spinal cord tissue in mice, the stem cell technology industry is poised to make great gains in the months and years ahead.

Maui General Store CEO Richard Miller commented that he is quite impressed with the technologies already developed by Trinity BioGenics: ``After seeking out the best possible match of potential returns for our shareholders, we are confident that Trinity BioGenics will continue to deliver revolutionary advances in the area of biological and stem cell therapy research. In addition to the obvious potential earnings from the commercialization of this industry, it makes sense to us on a humanistic level to support the growth of medical treatments that could significantly change the quality of life as we know it.``

The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company`s operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company`s dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.

The Maui General Store company logo can be found at: http://www.primezone.com/newsroom/prs/?pkgid=1128


Contact:

Maui General Store, Inc.
Richard Miller, President and CEO
Phone: [phone]

Source: Maui General Store

[wayne99]

Gestriger Schlusskurs:

MAUI GENERAL STORE (OTC BB:MAUG.OB)
Last Trade: 0.17
Trade Time: Dec 12
Change: Down 0.02 (10.99%)
Prev Close: 0.19
Open: 0.20
Bid: 0.17 x 5000
Ask: 0.18 x 5000
1y Target Est: N/A

Day`s Range: 0.17 - 0.22
52wk Range: 0.03 - 0.40
Volume: 1,286,021
Avg Vol (3m): 410,666
Market Cap: 24.35M

Zur MK noch folgendes:
Ca. 3Mio. Shares werden zurückgekauft - Meldung vom 6.12.05

Press Release Source: Maui General Store

Maui General Store to Raise Shareholder Equity through Retirement of Shares
Tuesday December 6, 7:00 am ET

HANA, Hawaii, Dec. 6, 2005 (PRIMEZONE) -- Richard Miller, President and CEO of Maui General Store (OTC BB:MAUG.OB - News) announced today that the company is retiring approximately three million shares of his Maui General Store Common Stock as part of a shareholder equity restructuring program in anticipation of the merger with Trinity Biogenics. Miller noted that this realignment will benefit Maui General Store shareholders as the company moves forward. Reducing the number of outstanding shares, Miller further explained, is a reasonable and prudent decision in light of current agreements the company has pending.

ADVERTISEMENT
The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company`s operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company`s dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.


Contact:

Maui General Store, Inc.
Richard Miller, President and CEO
[phone]
http://www.MauiGeneralStore.com

Source: Maui General Store

[Juppes13]

Hat sich überhaupt mal jemand schlau gemacht,
wer oder was Maui Generalstore eigentlich ist ?

Keine Informationen auf der etwas merkwürdigen Internetsite
ausser dem Merger mit TinityBioGenetics.


Kalter Kaffee

[wayne99]

ress Release Source: Maui General Store

Trinity BioGenics Acquires Lab and Intellectual Properties
Monday April 3, 7:00 am ET

CLEARWATER, Fla., April 3, 2006 (PRIMEZONE) -- Maui General Stores Inc. dba Trinity BioGenics Corp. (OTC BB:MAUG.OB - News), a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with Immune Therapy, is pleased to announce that it has acquired intellectual property and laboratory assets formerly owned by Patho Biotech. This acquisition is key to the Company's future development of commercial therapeutic & diagnostic products based on the identification of nano-bacteria.

ADVERTISEMENT
[0]
[0]
The Company's lab is operated by Dr. Luther Lindner, M.D. Dr. Lindner is a physician (pathologist) on the faculty of Texas A&M University -- College of Medicine. He is studying human blood bacterium, believed to be associated with chronic fatigue and immune dysfunction syndrome (CFIDS), fibromyalgia, and several autoimmune disorders including multiple sclerosis, lupus erythematosis, and rheumatoid arthritis.

Trinity BioGenics will use this facility to establish a research and processing laboratory to create commercial products only available via the CompanyÂÂ's license agreement for use nationally and abroad.

Trinity BioGenics CEO, Lawrence Stowe, stated, ``The acquisition of this laboratory marks an important moment in the history of Trinity BioGenics. With the potential of our newest facility we will be able to further develop our research capability, which is our primary objective at this moment in time.''

For all future Trinity BioGenics investor relations needs, investors are asked to visit the Trinity BioGenics IR Hub at http://www.agoracom.com/IR/TrinityBioGenics where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail] where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About Trinity BioGenics Corp.

Trinity BioGenics Corp works exclusively within the Adult Stem Cell and Biological Medicine areas. The Company's proprietary protocols are advanced, and use specific processes to obtain desired results. The FDA classifies the Company's process as a unique blood product; therefore, it will be specific and unique to Trinity BioGenics Corp. Additionally, the Company's unique combination of Immune Therapy and Adult Stem Cell treatments are like no other treatment experienced. The Company's Adult Stem Cell protocol is under preparation for Human Clinical Studies.

The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.


Contact:

Trinity BioGenics
Dr. Lawrence Stowe
727-491-3780
http://www.trinitybiogenics.com

Investor Relations
AGORA Investor Relations
http://www.agoracom.com/IR/TrinityBioGenics
[e-mail]

Source: Maui General Store